KGC vs. BBIO
KGC (Kinross Gold Corporation) and BBIO (BridgeBio Pharma, Inc.) are both stocks. KGC operates in Gold (Basic Materials), while BBIO operates in Biotechnology (Healthcare). Over the past 5 years, KGC returned 29.50%/yr vs 1.89%/yr for BBIO. At a 0.14 correlation, their price movements are largely independent.
Performance
KGC vs. BBIO - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, KGC achieves a -7.93% return, which is significantly higher than BBIO's -11.92% return.
KGC
- 1D
- -1.37%
- 1M
- -17.82%
- YTD
- -7.93%
- 6M
- -2.01%
- 1Y
- 72.32%
- 3Y*
- 76.89%
- 5Y*
- 29.50%
- 10Y*
- 18.75%
BBIO
- 1D
- -0.35%
- 1M
- -0.03%
- YTD
- -11.92%
- 6M
- -9.25%
- 1Y
- 74.44%
- 3Y*
- 61.48%
- 5Y*
- 1.89%
- 10Y*
- —
KGC vs. BBIO - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|---|
KGC Kinross Gold Corporation | -7.93% | 206.11% | 55.63% | 51.83% | -27.59% | -19.00% | 56.04% | 22.80% |
BBIO BridgeBio Pharma, Inc. | -11.92% | 178.75% | -32.03% | 429.79% | -54.32% | -76.54% | 102.88% | 27.22% |
Correlation
The correlation between KGC and BBIO is 0.14, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.14 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.16 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.19 |
Correlation (All Time) Calculated using the full available price history since Jun 28, 2019 | 0.14 |
Fundamentals
KGC:
$31.14B
BBIO:
$13.12B
KGC:
$2.35
BBIO:
-$3.76
KGC:
3.96
BBIO:
23.00
KGC:
$7.94B
BBIO:
$566.04M
KGC:
$4.19B
BBIO:
$538.20M
KGC:
$5.02B
BBIO:
-$602.24M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
KGC vs. BBIO — Risk / Return Rank
KGC
BBIO
KGC vs. BBIO - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Kinross Gold Corporation (KGC) and BridgeBio Pharma, Inc. (BBIO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| KGC | BBIO | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.17 | ||
| Sortino ratioReturn per unit of downside risk | -0.42 | ||
| Omega ratioGain probability vs. loss probability | 1.26 | 1.30 | -0.04 |
| Calmar ratioReturn relative to maximum drawdown | 2.28 | 3.70 | -1.42 |
| Martin ratioReturn relative to average drawdown | 6.11 | 9.25 | -3.15 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| KGC | BBIO | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.43 | 1.60 | -0.17 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.67 | 0.02 | +0.65 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.40 | — | — |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.08 | 0.16 | -0.09 |
Drawdowns
KGC vs. BBIO - Drawdown Comparison
The maximum KGC drawdown since its inception was -96.00%, roughly equal to the maximum BBIO drawdown of -92.80%. Use the drawdown chart below to compare losses from any high point for KGC and BBIO.
Loading charts...
Drawdown Indicators
| KGC | BBIO | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -96.00% | -92.80% | -3.20% |
Max Drawdown (1Y)Largest decline over 1 year | -31.89% | -20.25% | -11.64% |
Max Drawdown (3Y)Largest decline over 3 years | -31.89% | -49.08% | +17.19% |
Max Drawdown (5Y)Largest decline over 5 years | -60.31% | -91.89% | +31.58% |
Max Drawdown (10Y)Largest decline over 10 years | -67.75% | — | — |
Current DrawdownCurrent decline from peak | -31.89% | -15.69% | -16.20% |
Average DrawdownAverage peak-to-trough decline | -57.62% | -45.80% | -11.82% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 11.88% | 8.07% | +3.81% |
Volatility
KGC vs. BBIO - Volatility Comparison
Kinross Gold Corporation (KGC) has a higher volatility of 16.41% compared to BridgeBio Pharma, Inc. (BBIO) at 12.10%. This indicates that KGC's price experiences larger fluctuations and is considered to be riskier than BBIO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| KGC | BBIO | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 16.41% | 12.10% | +4.31% |
Volatility (6M)Calculated over the trailing 6-month period | 39.75% | 34.41% | +5.34% |
Volatility (1Y)Calculated over the trailing 1-year period | 50.78% | 46.75% | +4.03% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 44.07% | 85.95% | -41.88% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 46.95% | 83.80% | -36.85% |
Dividends
KGC vs. BBIO - Dividend Comparison
KGC's dividend yield for the trailing twelve months is around 0.56%, while BBIO has not paid dividends to shareholders.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
BBIO BridgeBio Pharma, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
KGC Kinross Gold Corporation | 0.56% | 0.44% | 1.29% | 1.98% | 2.93% | 2.69% | 0.82% |
Financials
KGC vs. BBIO - Financials Comparison
This section allows you to compare key financial metrics between Kinross Gold Corporation and BridgeBio Pharma, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
KGC vs. BBIO - Profitability Comparison
KGC - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Kinross Gold Corporation reported a gross profit of 1.37B and revenue of 2.37B. Therefore, the gross margin over that period was 57.8%.
BBIO - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, BridgeBio Pharma, Inc. reported a gross profit of 178.39M and revenue of 180.60M. Therefore, the gross margin over that period was 98.8%.
KGC - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Kinross Gold Corporation reported an operating income of 1.31B and revenue of 2.37B, resulting in an operating margin of 55.1%.
BBIO - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, BridgeBio Pharma, Inc. reported an operating income of -105.96M and revenue of 180.60M, resulting in an operating margin of -58.7%.
KGC - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Kinross Gold Corporation reported a net income of 831.32M and revenue of 2.37B, resulting in a net margin of 35.0%.
BBIO - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, BridgeBio Pharma, Inc. reported a net income of -164.04M and revenue of 180.60M, resulting in a net margin of -90.8%.
Frequently Asked Questions
KGC and BBIO have a correlation of 0.14, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
KGC has higher volatility (16.41%) compared to BBIO (12.10%). In terms of maximum drawdown, KGC dropped -96.00% vs BBIO's -92.80%.
BBIO currently has the higher Sharpe Ratio (1.60 vs 1.43), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for KGC and BBIO
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer